Sage fo­cus­es on suc­cess­ful launch of post­par­tum de­pres­sion drug

Last year
Pharma
Marketing

An­oth­er quar­ter, an­oth­er Keytru­da win for Mer­ck

Last year
R&D
Pharma

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

Last year
Pharma

Cere­vance's $47M raise; Parex­el's AI pact

Last year
News Briefing

Astel­las cuts a bis­pe­cif­ic in can­cer and a mi­to­chon­dria-fo­cused as­set from Mi­to­bridge deal

Last year
R&D
Pharma

Mer­ck KGaA to ex­pand Ger­man head­quar­ters with €300M+ re­search cen­ter 

Last year
R&D
Manufacturing

As­traZeneca’s Pas­cal So­ri­ot says new rise in pay is ‘re­al­ly about’ po­ten­tial suc­ces­sor

Last year
People
Pharma

Re­gen­eron and Mam­moth strike $100M deal to pair tiny CRISPR ed­i­tors with new de­liv­ery idea

Last year
Deals

Up­dat­ed: Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

Last year
Pharma

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Last year
R&D
China

Astel­las' Friedre­ich’s atax­ia gene ther­a­py cleared for clin­i­cal study af­ter ear­li­er ver­sion stum­bled

Last year
R&D
Cell/Gene Tx

Wal­greens will build out spe­cial­ty phar­ma­cy busi­ness, lean­ing in­to drug and ther­a­py ser­vices

Last year
Cell/Gene Tx
Health Tech

Bio­Mar­in's Roc­ta­vian strug­gles con­tin­ue. Is a di­vest­ment in the fu­ture?

Last year
Pharma
Cell/Gene Tx

Cidara buys back flu rights, sells an­ti­fun­gal and inks $240M PIPE

Last year
Financing
Deals

Fol­low­ing low­er-than-ex­pect­ed prof­its, Evotec plans to cut costs, com­pletes CEO search

Last year
People
Pharma

Sen. Sanders launch­es probe of Novo's We­govy and Ozem­pic pric­ing

Last year
Pharma

Neu­ro­crine launch­es CAH rare dis­ease ed­u­ca­tion cam­paign ahead of FDA sub­mis­sion

Last year
Pharma
Marketing

Ther­mo Fish­er ex­pects last­ing ben­e­fits to bill tar­get­ing Chi­nese ser­vice providers

Last year
China
Manufacturing

Roche un­ruf­fled by Chi­na bill as it looks to grow roots in the re­gion

Last year
China
Manufacturing

Can­cer test­ing com­pa­ny Freenome to lay off 100 em­ploy­ees

Last year
People

FDA's bi­o­log­ics chief Pe­ter Marks pre­views ac­cel­er­at­ed ap­proval guid­ance

Last year
R&D
Pharma

Ex­clu­sive: Op­tum is shut­ting down its vir­tu­al care busi­ness

Last year
People
Health Tech

Cure­Vac to cut costs, starts GSK-part­nered bird flu vac­cine tri­al

Last year
R&D
Pharma

8 take­aways from Bio­gen’s Q1 up­date: A ‘dif­fi­cult’ launch for Leqem­bi, a $103M vouch­er and a fo­cus on new ...

Last year
Pharma
First page Previous page 166167168169170171172 Next page Last page
A service from the Financial Times